With the MHRA becoming the standalone regulator of medicines in Great Britain, Precision research aims to shed light on market access in the post-Brexit era, as well as key implications for manufacturers. In this Access90, Precision’s Katherine Ka Wan Leong discusses two research posters the PRECISION team will be presenting at ISPOR US this year focusing on the UK access landscape.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
